SOUTH SAN FRANCISCO, Calif., March 8, 2023 /PRNewswire/ -- PACT Pharma, Inc., a privately held biopharmaceutical company developing transformational personalized neoantigen-specific and off-the-shelf T cell receptor (TCR)-T cell therapies for the eradication of solid tumors, today announced the publication of a peer-reviewed paper in Nature in collaboration with researchers at University of California, Los Angeles (UCLA) detailing groundbreaking work characterizing and differentiating the immune responses of melanoma patients treated with anti PD-1 immunotherapy.
In the world of precision oncology, it’s something like the Holy Grail: the ability to genetically fine-tune a cancer patient’s immune cells into weapons that target their specific tumor, without harming healthy tissue.
SOUTH SAN FRANCISCO, Calif., Nov. 2, 2022 /PRNewswire/ -- PACT Pharma, Inc., a privately held biopharmaceutical company developing transformational personalized neoantigen-specific and off-the-shelf T cell receptor (TCR) T cell therapies for the eradication of solid tumors, today announced that new data highlighting its first-of-its-kind adoptive T cell therapy platform will be featured in multiple presentations at the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022). The company, along with academic research collaborators, will deliver oral and poster presentations, including a late-breaking oral presentation, providing the latest clinical and preclinical findings from its pioneering research in the field of personalized neoantigen TCR T cell therapies. SITC 2022 is being held November 8-12, 2022, in Boston, Massachusetts.
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2022 /PRNewswire/ -- PACT Pharma, Inc., a privately held biopharmaceutical company developing transformational personalized neoantigen-specific and off-the-shelf T cell receptor (TCR) T cell therapies for the eradication of solid tumors, today announced that it has entered into an agreement to sell select assets to AmplifyBio, a contract research organization focused on accelerating innovation across pharmaceutical modalities. Under terms of the agreement, AmplifyBio will acquire advanced characterization platforms and bioinformatics capabilities from PACT to enhance the company's cell and gene therapy characterization capabilities. Additionally, AmplifyBio will acquire PACT's South San Francisco facility along with a number of technical operations and product characterization domain experts.
PACT Pharma is selling off a handful of assets plus its South San Francisco facility to contract research organization AmplifyBio in a bid to raise additional cash.
More than a month after PACT Pharma disclosed it would be laying off 94 employees, the company will instead be diverting more than half of those employees towards a new unnamed business development venture, according to CEO Scott Garland. Concurrent with the staffing shakeup, PACT is axing its lead program and refocusing its neoantigen-focused pipeline.
PACT Pharma has let go of 94 employees, leaving remaining staff to work on two clinical stage assets in immuno-oncology, according to a state workforce report in California.